NO20084997L - Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer - Google Patents

Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer

Info

Publication number
NO20084997L
NO20084997L NO20084997A NO20084997A NO20084997L NO 20084997 L NO20084997 L NO 20084997L NO 20084997 A NO20084997 A NO 20084997A NO 20084997 A NO20084997 A NO 20084997A NO 20084997 L NO20084997 L NO 20084997L
Authority
NO
Norway
Prior art keywords
pyrazolo
respiratory diseases
pyrimidine derivatives
derivatives useful
treating respiratory
Prior art date
Application number
NO20084997A
Other languages
English (en)
Inventor
Brian Cox
Ian Bruce
Judy Fox Hayler
Graham Charles Bloomfield
Lee Edwards
Catherine Howsham
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36687588&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084997(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20084997L publication Critical patent/NO20084997L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Den foreliggende oppfinnelsen angår en forbindelse av formel (I) eller et farmasøytisk akseptabelt salt eller solvat derav, hvor R1-R3 og Y er definert i beskrivelsen, og dens anvendelse i behandlingen av lidelser hvor pi3 kinase er implisert.
NO20084997A 2006-05-23 2008-11-28 Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer NO20084997L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0610242.0A GB0610242D0 (en) 2006-05-23 2006-05-23 Organic compounds
PCT/EP2007/004501 WO2007134828A1 (en) 2006-05-23 2007-05-21 Pyrazolo [3, 4-d] pyrimidine derivatives useful to treat respiratory disorders

Publications (1)

Publication Number Publication Date
NO20084997L true NO20084997L (no) 2008-12-22

Family

ID=36687588

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084997A NO20084997L (no) 2006-05-23 2008-11-28 Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer

Country Status (24)

Country Link
US (5) US20090131457A1 (no)
EP (1) EP2026811A1 (no)
JP (1) JP2009537580A (no)
KR (1) KR101106853B1 (no)
CN (1) CN101443013A (no)
AR (2) AR061057A1 (no)
AU (1) AU2007253615B2 (no)
BR (1) BRPI0712022A2 (no)
CA (1) CA2650661A1 (no)
CL (1) CL2007001455A1 (no)
CR (1) CR10419A (no)
EC (1) ECSP088902A (no)
GB (1) GB0610242D0 (no)
GT (1) GT200800256A (no)
IL (1) IL195017A0 (no)
MA (1) MA30433B1 (no)
MX (1) MX2008014835A (no)
NO (1) NO20084997L (no)
PE (1) PE20080315A1 (no)
RU (1) RU2008150619A (no)
TN (1) TNSN08478A1 (no)
TW (1) TW200806665A (no)
WO (1) WO2007134828A1 (no)
ZA (1) ZA200809097B (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
MX2008012928A (es) 2006-04-04 2009-03-06 Univ California Antagonistas de pi3-cinasa.
CA2694275A1 (en) * 2007-07-26 2009-01-29 Novartis Ag Organic compounds
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2009046448A1 (en) 2007-10-04 2009-04-09 Intellikine, Inc. Chemical entities and therapeutic uses thereof
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2111861A1 (en) * 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CA2725014C (en) 2008-05-30 2014-06-17 Amgen Inc. Inhibitors of pi3 kinase
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US8220787B2 (en) * 2008-09-19 2012-07-17 Panasonic Corporation Part mounting device
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US8697709B2 (en) 2008-10-16 2014-04-15 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2756871A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
JP2013506691A (ja) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファチジルイノシトール３−キナーゼのピラゾール阻害薬
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2571361A4 (en) * 2010-05-19 2013-11-13 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
WO2012148540A1 (en) 2011-02-23 2012-11-01 Intellikine, Llc Combination of kanase inhibitors and uses threof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
GB201115853D0 (en) 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
EP2755974A1 (en) 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
ES2650630T3 (es) 2011-10-03 2018-01-19 The University Of North Carolina At Chapel Hill Compuestos de pirrolopirimidina para el tratamiento del cáncer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2015517574A (ja) 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2015115631A (ru) 2012-09-26 2016-11-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Модулирование ire1
WO2014062774A1 (en) 2012-10-17 2014-04-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
EP3129377A4 (en) 2014-04-11 2017-12-20 The University of North Carolina at Chapel Hill Mertk-specific pyrimidine compounds
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CZ308056B6 (cs) * 2015-07-20 2019-11-27 Ustav Experimentalni Botaniky Av Cr V V I 5-Substituované-7-[4-(substituované)benzyl]amino-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako antirevmatika, a farmaceutické přípravky
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
ES2886587T3 (es) 2016-04-15 2021-12-20 Cancer Research Tech Ltd Compuestos heterocíclicos como inhibidores de la quinasa RET
US10844067B2 (en) 2016-04-15 2020-11-24 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2018016227A (es) 2016-06-24 2019-07-08 Infinity Pharmaceuticals Inc Terapias de combinacion.
JOP20180009A1 (ar) * 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR205429A1 (es) * 1971-04-27 1976-05-07 Ciba Geigy Ag Procedimiento para la elaboracion de nuevos derivados de 4-amino - 3-(5-nitro- 2 -furil)-1-metil - 1h - pirazol-(3,4-ol)-pirimidina
AR205234A1 (es) * 1974-05-13 1976-04-12 Lilly Co Eli Procedimiento p a r a preparar compuestos de 3-(5-nitroimidazol-2-il) pirazolo (3,4-d) pirimidina
US4044130A (en) * 1974-07-03 1977-08-23 Ciba-Geigy Corporation Compositions for the control of microorganisms
JPS5195094A (en) * 1975-01-31 1976-08-20 * ***** ****so*shi***** *o*u****** ********ne***u**** *** *** ****ne*** *************te***ku**
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
EP1212327B8 (en) * 1999-09-17 2004-02-25 Abbott GmbH & Co. KG Pyrazolopyrimidines as therapeutic agents
ATE502941T1 (de) * 2000-04-25 2011-04-15 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta
ES2309206T3 (es) * 2001-10-02 2008-12-16 Smithkline Beecham Corporation Compuestos quimicos.
AU2003225933A1 (en) * 2002-03-22 2003-10-13 Cellular Genomics, Inc. AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
WO2006068760A2 (en) * 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity

Also Published As

Publication number Publication date
GB0610242D0 (en) 2006-07-05
GT200800256A (es) 2009-05-28
KR101106853B1 (ko) 2012-01-19
KR20090008392A (ko) 2009-01-21
US20160303132A1 (en) 2016-10-20
US8901134B2 (en) 2014-12-02
PE20080315A1 (es) 2008-06-11
TW200806665A (en) 2008-02-01
RU2008150619A (ru) 2010-06-27
US20180125849A1 (en) 2018-05-10
US20090131457A1 (en) 2009-05-21
ZA200809097B (en) 2009-11-25
MA30433B1 (fr) 2009-05-04
CN101443013A (zh) 2009-05-27
CL2007001455A1 (es) 2008-05-16
AU2007253615A1 (en) 2007-11-29
AR061057A1 (es) 2008-07-30
TNSN08478A1 (en) 2010-04-14
EP2026811A1 (en) 2009-02-25
MX2008014835A (es) 2008-12-01
BRPI0712022A2 (pt) 2011-12-27
AR110051A2 (es) 2019-02-20
CA2650661A1 (en) 2007-11-29
ECSP088902A (es) 2008-12-30
WO2007134828A1 (en) 2007-11-29
US20140235632A1 (en) 2014-08-21
JP2009537580A (ja) 2009-10-29
AU2007253615B2 (en) 2011-06-23
CR10419A (es) 2011-07-19
IL195017A0 (en) 2009-08-03
US20140051698A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
NO20084997L (no) Pyrazolo[3,4-D]pyrimidinderivater nyttige for a behandle andedrettssykdommer
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2007007919A3 (en) Heterocyclic janus kinase 3 inhibitors
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BR112013014184A2 (pt) compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso
MEP45608A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, and processes for preparing them
NO20064201L (no) Glukopyranosylsubstituerte benzolderivater, medikamenter inneholdende slike forbindelser, deres anvendelse og fremstilling
NO20062136L (no) Imidazopyrazintyrosin-kinaseinhibitorer
IL166412A0 (en) Novel use of benzothiazole derivatives
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
WO2008094909A3 (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
MEP58708A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
ATE365742T1 (de) 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren
MX2009011812A (es) Aminopirimidinas utiles como inhibidores de cinasa.
EA201200875A1 (ru) Ингибиторы сфингозинкиназы
NO20091254L (no) Terapeutiske sammensetninger
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
MX2023010087A (es) Derivados heterociclicos como inhibidores de cinasas jano.
WO2008109856A3 (en) Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application